Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disorder characterized primarily by impaired movement, but it also produces important cognitive, psychiatric, autonomic, sleep, and sensory symptoms.

The disease is closely associated with degeneration of dopamine-producing neurons within the substantia nigra pars compacta, a region of the midbrain that plays a critical role in the basal ganglia motor system.

As dopaminergic signaling declines, patients gradually develop the characteristic features of Parkinsonism, including bradykinesia, rigidity, resting tremor, and, later in the disease course, postural instability.

What Happens in Parkinson’s Disease?

The major pathological abnormality in Parkinson’s disease is progressive loss of dopaminergic neurons in the substantia nigra. These neurons normally project to the striatum, where dopamine helps regulate smooth, coordinated movement.

↓ Dopamine production → Altered basal ganglia signaling → Impaired movement initiation and control

By the time characteristic motor symptoms become clinically apparent, substantial dopaminergic neuronal dysfunction has already occurred. Another major pathological hallmark is the presence of Lewy bodies and Lewy neurites—intracellular inclusions containing abnormal aggregates of proteins, particularly alpha-synuclein.

Epidemiology

Parkinson’s disease becomes increasingly common with age and most frequently develops in adults over 60 years of age. Young-onset Parkinson’s disease may occur before age 50 and may warrant careful evaluation for genetic or alternative causes. PD affects both men and women, with epidemiological studies generally demonstrating a higher prevalence among men.

The Cardinal Motor Features

Modern diagnostic approaches place particular emphasis on bradykinesia combined with either rigidity or rest tremor when identifying Parkinsonism.

Cardinal Feature	Clinical Description	Key Clinical Characteristics
Bradykinesia	Slowness of movement accompanied by progressive reduction in speed or amplitude during repetitive voluntary movements.	Difficulty initiating movement, reduced hand dexterity, micrographic handwriting, masked facies (hypomimia), soft speech (hypophonia), and decrement during repetitive actions such as finger tapping.
Resting Tremor	Typically a 4–6 Hz tremor occurring when the affected limb is at rest.	Often begins asymmetrically; may produce the classic “pill-rolling” motion of the thumb and fingers; commonly decreases with voluntary movement and may worsen with emotional stress. Absence of tremor does not exclude PD.
Rigidity	Increased resistance to passive movement of a joint.	Lead-pipe rigidity: relatively uniform resistance throughout passive movement. Cogwheel rigidity: a ratcheting sensation that may result from rigidity superimposed with tremor. Rigidity can contribute to discomfort and reduced arm swing.
Postural Instability	Impairment of postural reflexes resulting in reduced balance and stability.	Typically develops later in the disease course and may contribute to falls, difficulty turning, and loss of independence. Early prominent postural instability should raise suspicion for atypical Parkinsonism or another diagnosis.

Clinical Pearl: Not every patient with Parkinson’s disease develops a prominent tremor. Absence of tremor does not exclude PD.

Parkinsonian Gait Characteristics

• Shortened stride length and shuffling steps
• Reduced foot clearance and stooped posture
• Reduced arm swing, often asymmetrically early in the disease
• Festination: Steps may become progressively shorter and faster
• Freezing of Gait: A transient inability or marked difficulty initiating or continuing stepping, often described as the feet feeling “stuck to the floor,” particularly when starting to walk, turning, or navigating narrow spaces

Non-Motor Symptoms & Prodrome

Parkinson’s disease is a multisystem disorder, and non-motor manifestations may appear years before classic motor deficits emerge.

• Psychiatric & Cognitive: Depression, anxiety, apathy, executive dysfunction, slowed processing speed, cognitive impairment, and hallucinations in some patients.
• Autonomic: Constipation, orthostatic hypotension, urinary dysfunction, sexual dysfunction, and abnormal sweating.
• Sleep: REM sleep behavior disorder (RBD), insomnia, excessive daytime sleepiness, and fragmented sleep.
• Sensory: Hyposmia or anosmia, pain, and other sensory disturbances.

Clinical Pearl: Hyposmia, constipation, depression, and REM sleep behavior disorder may precede the characteristic motor manifestations of Parkinson’s disease by years.

Parkinson’s Disease Dementia vs. Dementia With Lewy Bodies

Distinguishing these closely related neurodegenerative conditions relies heavily on the temporal relationship between the development of dementia and Parkinsonian motor symptoms.

• Parkinson’s Disease Dementia (PDD): Parkinson’s disease is well established, with motor symptoms present for more than 1 year before dementia develops.
• Dementia With Lewy Bodies (DLB): Dementia develops before, concurrently with, or within 1 year of the onset of Parkinsonian motor symptoms. Common features include recurrent visual hallucinations, cognitive fluctuations, REM sleep behavior disorder, and Parkinsonism.

Clinical Pearl: The commonly used “1-year rule” distinguishes PDD from DLB based on the timing of dementia relative to Parkinsonian motor symptoms.

Differential Diagnosis

Several neurological and systemic disorders can mimic Parkinson’s disease and should be considered during clinical assessment.

• Atypical Parkinsonism: Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), and Corticobasal Syndrome (CBS).
• Secondary Causes: Drug-induced Parkinsonism, particularly from dopamine receptor-blocking medications; vascular Parkinsonism; Normal Pressure Hydrocephalus (NPH); and structural central nervous system lesions.
• Metabolic Disorders: Wilson disease, an inherited disorder of copper metabolism that may present in younger patients with tremor, rigidity, dystonia, psychiatric changes, and hepatic dysfunction.

Diagnostic Evaluation

Parkinson’s disease remains primarily a clinical diagnosis based on a detailed patient history, medication review, comprehensive neurological examination, and assessment of the clinical response to dopaminergic therapy when appropriate.

• Laboratory Testing: No routine blood biomarker currently establishes a diagnosis of idiopathic PD. In younger patients or when Wilson disease is clinically suspected, serum ceruloplasmin and urinary copper testing may be considered.
• Brain MRI: MRI is not routinely required in a classic presentation but may be used selectively to identify or exclude alternative causes such as stroke, structural lesions, Normal Pressure Hydrocephalus, or features suggesting atypical Parkinsonism.

Pharmacological Management

Symptomatic management is individualized according to functional impairment, age, disease stage, cognitive status, motor complications, comorbidities, and the patient’s specific motor and non-motor symptom profile.

Medication Class	Representative Agents	Clinical Role & Key Considerations
Levodopa / Carbidopa	Sinemet and other immediate-release or extended-release carbidopa/levodopa formulations; inhaled levodopa is also available for selected OFF episodes	Most effective symptomatic motor therapy. Levodopa crosses the blood-brain barrier and is converted to dopamine. Carbidopa reduces peripheral levodopa metabolism, allowing more levodopa to reach the CNS while decreasing peripheral adverse effects such as nausea. Long-term treatment may be associated with wearing-off and dyskinesias.
Dopamine Agonists	Pramipexole, Ropinirole, Rotigotine, Apomorphine	Directly stimulate dopamine receptors and may be used as monotherapy in selected patients or as adjunctive treatment. Adverse effects include somnolence, hallucinations, orthostatic hypotension, edema, and impulse-control disorders such as compulsive gambling, shopping, eating, or sexual behavior. Apomorphine may be used as rapid rescue therapy for selected OFF episodes.
MAO-B Inhibitors	Selegiline, Rasagiline, Safinamide	Reduce central dopamine metabolism. They may provide modest symptomatic benefit and can be used as adjunctive therapy to reduce OFF time.
COMT Inhibitors	Entacapone, Opicapone, Tolcapone	Prolong the effect of levodopa by reducing its metabolism and are used as adjunctive therapy for wearing-off. Tolcapone carries a risk of serious hepatotoxicity and requires appropriate liver monitoring.
NMDA Receptor Antagonist	Amantadine	Frequently used to reduce levodopa-induced dyskinesia and may also provide modest benefit for Parkinsonian symptoms. Adverse effects include confusion, hallucinations, livedo reticularis, and peripheral edema.
Anticholinergics	Benztropine, Trihexyphenidyl	May improve tremor in carefully selected younger patients. They are generally avoided in older adults and patients with cognitive impairment because of risks including confusion, memory impairment, urinary retention, constipation, blurred vision, and delirium.

Clinical Pearl: Levodopa remains the most effective symptomatic medication for the motor manifestations of Parkinson’s disease. Treatment decisions should be individualized according to symptoms and functional impairment rather than routinely delaying levodopa solely because of patient age.

Managing Long-Term Motor Complications

• Wearing-Off (Motor Fluctuations): The return of Parkinsonian symptoms before the next scheduled levodopa dose. Management may include adjusting dose timing or formulation and adding medications such as COMT inhibitors, MAO-B inhibitors, or dopamine agonists when appropriate.
• Levodopa-Induced Dyskinesia: Involuntary choreiform, swaying, twisting, or other abnormal movements that may occur during periods of high levodopa effect. Management may include adjustment of levodopa dosing strategies or treatment with amantadine.

Managing Non-Motor & Neuropsychiatric Complications

• Parkinson’s Disease Psychosis: May present with visual hallucinations, illusions, paranoia, or delusions. Antipsychotics with strong dopamine D2 receptor blockade, including many typical antipsychotics such as haloperidol, are generally avoided because they can substantially worsen Parkinsonian motor symptoms. Depending on the clinical situation, treatment options may include Pimavanserin, Quetiapine, or Clozapine. Clozapine requires appropriate absolute neutrophil count (ANC) monitoring because of the risk of severe neutropenia.
• Parkinson’s Disease Dementia: Cholinesterase inhibitors may be considered, with Rivastigmine being an established treatment option. Minimizing unnecessary anticholinergic medication burden is particularly important.
• Depression & Anxiety: Management may include SSRIs, SNRIs, psychotherapy, exercise, and individualized behavioral or social interventions.

Advanced Surgical Interventions

When optimized pharmacological therapy does not adequately control motor fluctuations, medication-refractory tremor, or dyskinesias, advanced interventions may be considered.

• Deep Brain Stimulation (DBS): DBS involves surgically implanted electrodes that commonly target the Subthalamic Nucleus (STN) or Globus Pallidus Internus (GPi). In appropriately selected patients, DBS can substantially improve medication-responsive motor symptoms, refractory tremor, motor fluctuations, and dyskinesia. DBS does not stop neurodegenerative disease progression or reverse established dementia, and significant cognitive impairment generally makes a patient a poor candidate for the procedure.
• Ablative Procedures: Procedures such as pallidotomy or thalamotomy create a targeted lesion within specific motor circuits. Traditional surgical lesioning has largely been replaced by DBS in many settings, although modern lesioning approaches, including focused ultrasound in selected patients, remain therapeutic options.

Multidisciplinary Non-Pharmacological Care

• Physical Therapy & Exercise: Aerobic exercise, resistance training, gait training, balance exercises, cueing strategies, and activities such as Tai Chi may improve mobility, balance, gait performance, functional independence, and fall prevention.
• Occupational Therapy: Occupational therapists can assist with activities of daily living (ADLs), home safety modifications, adaptive equipment, handwriting difficulties, workplace modifications, and driving-related assessment.
• Speech & Swallowing Therapy: Speech-language therapy can address hypophonia, articulation, communication, and swallowing impairment. Formal swallowing assessment is important when dysphagia is suspected because progressive swallowing dysfunction can increase the risk of aspiration and aspiration pneumonia.

Clinical Takeaways

• PD is characterized by progressive dysfunction and loss of dopaminergic neurons in the substantia nigra and is commonly associated with alpha-synuclein-containing Lewy pathology.
• Bradykinesia is required to establish Parkinsonism clinically and occurs in combination with rest tremor, rigidity, or both.
• Prominent postural instability typically develops later; early recurrent falls or severe balance impairment should raise concern for an alternative or atypical Parkinsonian syndrome.
• Prodromal features such as hyposmia, constipation, and REM sleep behavior disorder may precede motor manifestations by years.
• Levodopa/carbidopa remains the cornerstone and most effective symptomatic treatment for Parkinsonian motor symptoms.
• Dopamine agonists can cause important adverse effects, particularly impulse-control disorders, somnolence, hallucinations, and orthostatic hypotension.
• Strong dopamine-blocking antipsychotics can significantly worsen Parkinsonism and should generally be avoided. Parkinson’s disease psychosis requires careful medication selection.
• Deep Brain Stimulation targeting the STN or GPi can provide substantial motor benefit in carefully selected patients with appropriate treatment-responsive symptoms.
• Comprehensive management frequently involves physical therapy, occupational therapy, speech-language pathology, exercise, medication management, and ongoing assessment of cognitive, psychiatric, autonomic, sleep, and other non-motor symptoms.

Educational content only. Parkinson’s disease diagnosis and treatment should be individualized according to current neurological guidance, disease stage, medication response, cognitive status, comorbidities, and patient-specific goals.